GN-HEARING
3.5.2021 09:02:09 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils Interton Move , the newest addition to its leading portfolio of hearing solutions that caters to all user needs. Interton Move makes great sound quality and best-in-class connectivity more accessible, helping hearing care professionals meet the diverse needs of people living with hearing loss.
The lineup of 10 essential hearing aids represents the biggest upgrade in the history of Interton. People from across the hearing loss spectrum can now get more out of life with greater choice than ever before. Most importantly, people can now feel confident when communicating with friends and family as they can focus on what they want to hear. They benefit from improved listening comfort in different environments, made possible thanks to a new, faster, more powerful sound processing platform. The launch also presents new rechargeability options and full smartphone support with direct audio streaming and an app for personalization. These vital elements result in high-quality, yet affordable hearing care with all the benefits of GN’s leading and proven technology.
Globally, 430 million people live with hearing loss and only 1 in 5 people who could benefit from hearing aids actually use them.1 Untreated hearing loss has wide-reaching impacts on a person’s quality of life and happiness. As hearing loss can be perceived by some as a small problem and something to ignore or put up with, hearing aids may be seen as an overwhelming solution. With the new Interton Move portfolio, hearing care professionals can now offer simple and straightforward hearing care to more people than ever before.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we want to make life sound better for every person with hearing loss. Treating hearing loss can radically transform an individual’s life, as they can hear more and return to doing what they love. With the launch of Interton Move, we’re pleased to support the crucial role that hearing care professionals play in helping people access the hearing care they need.”
The extensive portfolio includes a mini rechargeable Receiver-in-Ear (RIE), a mini Behind-the-Ear (BTE), custom hearing aids, and even a ‘Super Power’ option for profound hearing loss. The rechargeable RIE model and its matching desktop charger provide freedom from batteries and up to 30 hours of use on a single charge.
All Interton Move users can enjoy high-quality streaming of calls, music, and other audio directly from compatible Apple and AndroidTM devices. Meanwhile, the Interton Sound smartphone app enables users to personalize their hearing experience and connect to GN’s extensive range of wireless accessories.
All aspects of the fitting and onboarding process have been upgraded to improve the user experience and to ensure that the start of a person’s hearing journey is as seamless as possible. To make consulting easier for hearing care professionals, the Interton Fitting Software follows the same workflow as all other GN Hearing solutions.
Interton Move will roll out globally and be available in the first countries from May 2021.
NOTES TO EDITORS
About Interton
Interton was founded in Germany in 1962 and is part of the GN Group. Interton hearing aids are designed in Denmark and powered by pioneering technology that has transformed the sound quality, functionality, and comfort of hearing aids.
Visit our homepage interton.com – and connect with us on Facebook.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com and connect with us on LinkedIn and Facebook .
© 2021 GN Hearing A/S. All rights reserved. Interton is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
1 WHO: Deafness and hearing loss: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss . Accessed on April 12, 2021. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005229/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom